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Abstract
The molecular events in chordoma pathogenesis have not been fully delineated, particularly with respect to copy number
changes. Understanding copy number alterations in chordoma may reveal critical disease mechanisms that could be
exploited for tumor classification and therapy. We report the copy number analysis of 21 sporadic chordomas using array
comparative genomic hybridization (CGH). Recurrent copy changes were further evaluated with immunohistochemistry,
methylation specific PCR, and quantitative real-time PCR. Similar to previous findings, large copy number losses, involving
chromosomes 1p, 3, 4, 9, 10, 13, 14, and 18, were more common than copy number gains. Loss of CDKN2A with or without
loss of CDKN2B on 9p21.3 was observed in 16/20 (80%) unique cases of which six (30%) showed homozygous deletions
ranging from 76 kilobases to 4.7 megabases. One copy loss of the 10q23.31 region which encodes PTEN was found in 16/20
(80%) cases. Loss of CDKN2A and PTEN expression in the majority of cases was not attributed to promoter methylation. Our
sporadic chordoma cases did not show hotspot point mutations in some common cancer gene targets. Moreover, most of
these sporadic tumors are not associated with T (brachyury) duplication or amplification. Deficiency of CDKN2A and PTEN
expression, although shared across many other different types of tumors, likely represents a key aspect of chordoma
pathogenesis. Sporadic chordomas may rely on mechanisms other than copy number gain if they indeed exploit T/
brachyury for proliferation.
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Introduction
Chordoma is an uncommon malignant neoplasm with noto-
chord differentiation that most often arises in the axial skeleton.
The tumor is usually sporadic and rarely occurs as a familial case
or a component of a syndrome. Chordoma has a long clinical
course as it is typically slow growing; metastases tend to develop
years after initial diagnosis. Regardless, it is often locally
aggressive, and has a high rate of recurrence when not widely
excised. Adequate excision is frequently difficult because of tumor
proximity to the central nervous system and other vital structures.
Chordoma has a phenotype that recapitulates the notochord
which is the precursor to and essential in the formation of the axial
skeleton. Approximately 50% of chordomas arise in the sacrum,
35% in the skull base, and 15% in the mobile spine [1], while rare
cases have been reported to originate in an extra-axial distribution
or within soft tissues [2], [3]. Histologically, classic chordoma is
composed of nests and cords of tumor cells with abundant
eosinophilic or clear vacuolated cytoplasm and are enmeshed in
abundant myxoid stroma. Recent studies based on biochemical
analysis and immunohistochemistry have suggested that there may
be a potential role for molecular therapy in the treatment of
chordomas [4], [5], [6]. Although the morphology and immuno-
profile of chordoma is well recognized, the genetic mechanisms
underlying the development of the tumor have not been fully
characterized. Understanding these processes is important as they
govern the biological behavior of the neoplasm and may harbor
potential relevant targets for therapy.
Karyotype analysis of chordomas has revealed several recurrent
abnormalities. Losses of chromosome 1p and 3p short arms are
frequently observed and implicated in the early development of
the tumor [7], [8]. Chromosomal gains involving 7q, 20, 5q, and
12q, have been observed in at least 38% of cases studied although
their relevance remains to be elucidated [8]. A few familial cases
with linkage to 7q33 have been reported [9]. T (brachyury) gene
duplication has been recently identified as a major susceptibility
factor in familial chordoma by linkage analysis, high resolution
array comparative genomic hybridization (CGH), and quanti-
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another study demonstrated T copy number gain in a fraction of
sporadic chordomas and linked tumor proliferation to brachyury
expression [11]. Interestingly, chordoma has been identified in
patients with tuberous sclerosis complex (TSC) suggesting a
possible role of the TSC gene in the pathogenesis of the disease
[12]. Other specific defects implicated in chordoma include
abnormalities in the retinoblastoma tumor suppressor gene [13],
p53 [14], and the gene for cyclin-dependent kinase inhibitor 2A
and 2B [15]. The loss of the latter putative genes, CDKN2A and
CDKN2B, was identified in 70% of classical chordoma biopsies
evaluated with bacterial artificial chromosome (BAC) array CGH.
The application of non-biased, genome-wide approaches such
as array CGH provides the greatest potential to discover
unbalanced loci and candidate genes associated with disease
which otherwise would not have been covered with low resolution
and/or low throughput techniques such as karyotyping and FISH.
To further understand the molecular pathogenesis of chordoma
we utilized a genome-wide high-resolution oligonucleotide micro-
array to detect copy number changes in a set of 21 sporadic
chordoma tissue specimens.
Materials and Methods
Patient data and tumor specimen
This study was conducted with the approval of the Massachu-
setts General Hospital Institutional Review Board (protocol 2008-
P-000115/1; MGH) using anonymized, discarded clinical speci-
mens. The study group consisted of 21 fresh frozen tumor tissue
samples from histologically confirmed sporadic chordomas. Frozen
section slides from each sample were generated and examined to
substantiate the presence of adequate tumor cellularity prior to
analysis.
Array Comparative Genomic Hybridization Analysis
Genomic DNA was extracted from frozen tissue using the
Gentra Puregene Blood Kit (QIAGEN, Valencia, CA). Genome-
wide copy number alterations were analyzed by array comparative
genomic hybridization using the Agilent 244K oligonucleotide
array (Santa Clara, CA). The array contains more than 236,000
probes covering both coding and noncoding human sequences
with an overall median probe spacing of 8.9 kb (7.4 kb in Refseq
genes). Briefly, 0.5 micrograms (mg) of male human genomic
control DNA (Promega, Madison, WI) and 0.5 mg of tumor DNA
were digested with AluI and RsaI. Control and tumor DNA were
labeled by random priming (BioPrime Array CGH Labeling
Module, Invitrogen, Carlsbad, CA) with CY3- and CY5-dUTP
dyes, respectively (GE Healthcare, Piscataway, NJ). The labeled
DNA were purified with the Millipore Microcon YM-30 centrifugal
filter device (Billerica, MA) and mixed in equal proportion
for hybridization to the array in the presence of Cot-1
DNA (Invitrogen) using the Agilent Oligo CGH Hybridization Kit
(Santa Clara, CA). Hybridization steps included 3 minutes
denaturation at 95uC, pre-hybridization for 30 minutes at 37uC,
and hybridization for 35 to 40 hours at 65uC. Following
hybridization, the slides were washed with Agilent Oligo Array
CGH Wash Buffer 1 and Buffer 2, at room temperature for
5 minutes and at 37uC for one minute, respectively. A final third
wash was performed in stabilization and drying solution. Washed
slides were scanned using the Agilent G2565 Microarray Scanner
(Santa Clara, CA). Microarray TIFF (.tif) images were processed
with Agilent’s Feature Extraction Software v9.1 for data extraction.
Array data was analyzed with the Agilent Genomic Workbench
Standard Edition 5.0 software. Copy number aberration calls were
made with a minimum regional absolute average log base 2 ratio of
0.25 and minimumcontiguousprobe count of5.Allarraydata were
also manually reviewed for subtle copy number changes not
detected by the software.
CDKN2A (p16) Immunohistochemistry
Immunohistochemical studies were performed on formalin-
fixed, paraffin-embedded tissue in all cases using the standard
avidin-biotin-immunoperoxidase complex method. Prediluted p16
antibody was purchased from MTM Laboratories, Inc. (Heidel-
berg, Germany).
PTEN Immunofluorescence
Double immunofluorescence staining was performed as previ-
ously described [16]. Briefly, after deparaffinization and rehydra-
tion, slides were subjected to microwave epitope retrieval in
7.5 mM sodium citrate buffer, pH 6. After rinsing several times in
10 mM Tris HCL buffer, pH 8 containing 0.154 M NaCl (TBS)
supplemented with 0.05% (v/v) Tween-20 (TBST), endogenous
peroxidase activity was blocked with 2.5% (v/v) H2O2 in methanol
for 30 minutes. Non-specific binding of the antibodies was
extinguished by a 30 minute incubation with ‘‘Background
Sniper’’ (BioCare Medical, Concord, CA). The slide was then
incubated with the tumor specific antibody, wide spectrum
cytokeratin (DAKO, Carpinteria, CA, Z0622, Rabbit polyclonal
antibody, 1:250) overnight at 4C. The slides were washed with
TBST twice for 5 minutes and then once with TBS for 5 minutes.
The slides were incubated with the antibody to PTEN (Mouse
monoclonal antibody, Novocastra, Newcastle, UK 1:200) for
60 minutes at room temperature. Slides were then washed as
described above and incubated with a combination of goat anti-
rabbit IgG conjugated to AF555 (Molecular probes, Carlsbad, CA,
A21424, 1:200) in goat anti-mouse Envision+ (DAKO, Carpin-
teria, CA) for 60 minutes at room temperature in a dark humidity
tray. The slides were washed as described above, and the target
image was developed by a CSA reaction of Cy5 labeled tyramide
(PerkinElmer, Waltham, MA, 1:50). The slides were washed with
3 changes of TBS and stained with the DNA staining dye 49,
6-diaminodo-2-phenylindole (DAPI) in a non-fading mounting
media (ProLong Gold, Molecular probes, Carpinteria, CA). The
slides were allowed to dry overnight in a dark dry chamber, and
the edges were sealed.
The AQUA system (Software v2.2, HistoRx, New Haven, CT)
was used for the automated image acquisition and analysis [16].
Briefly, images of each slide were captured with an Olympus
BX51 microscope at 3 different extinction/emission wavelengths.
Within each slide, the area of tumor was distinguished from
stromal and necrotic areas by creating a tumor specific mask from
the anti-cytokeratin stain, which was visualized from the Alexa-
fluor 555 signal. The DAPI image was used to differentiate
between the cytoplasmic and nuclear staining within the tumor
mask. Finally, the fluorescence pixel intensity of the PTEN
protein/antibody complex was obtained from the Cy5 signal with
pixel intensity from 0–2000.
SNaPshot Assay
A single base extension SNaPshot assay evaluating common
point mutations in 13 cancer genes (APC, BRAF, CTNNB1, EGFR,
FLT3, JAK2, KIT, KRAS, NOTCH1, NRAS, PIK3CA, PTEN, and
TP53) was performed according to the manufacturer’s protocol
(Applied Biosystems (ABI), Foster City, CA). Tumor DNA was
amplified with eight multiplex PCR reactions followed by
treatment with exonuclease I and shrimp alkaline phosphatase
(USBWeb, Cleveland, OH). The amplified DNA served as
Copy Number Changes in Sporadic Chordomas
PLoS ONE | www.plosone.org 2 May 2011 | Volume 6 | Issue 5 | e18846templates for multiplex single base primer extension. Genotyping
primer extension products were analyzed with the ABI 3730
capillary electrophoresis system. Assay design and detailed
protocol have been previously described [17].
CDKN2A and PTEN Promoter Methylation Specific PCR
Purified genomic DNA from chordoma cases were bisulfite
treated using the Zymo Research EZ DNA Methylation-Gold
TM.
Promega Human Genomic DNA:Male (Madison, WI) was used as
the genomic unmethylated control. The same Promega genomic
control DNA was globally methylated with M. SssI CpG
Methyltransferase (New England Biolabs, Ipswich, MA) following
the manufacturer’s protocol to generate a methylated genomic
DNA control. Following desulphonation and clean-up, DNA was
eluted with 30 mL of the supplied elution buffer. Bisulfite treated
DNA (2 mL) was analyzed with methylated or unmethylated
specific primers by PCR (5 pmol of forward [Forw] and reverse
[Rev] primers, 200 mM dNTP, 1.2 mM MgCl2, and 0.5 U
Platinum Taq Polymerase in 10 mL total reaction volume; all
reagents from Invitrogen, Carlsbad, CA). CDKN2A promoter
analysis was performed with the following two previously reported
primer sets: p16-M Forw TTATTAGAGGGTGGGGCG-
GATCGC, p16-M Rev GACCCCGAACCGCGACCGTAA,
p16-U Forw TTATTAGAGGGTGGGGTGGATTGT, p16-U
Rev CAACCCCAAACCACAACCATAA, p16-M2 Forw TTAT-
TAGAGGGTGGGGCGGATCGC, p16-M2 Rev CCACC-
TAAATCGACCTCCGACCG, p16-U2 Forw TTATTAGAG-
GGTGGGGTGGATTGT, and p16-U2 Rev CCACCTAAAT-
CAACCTCCAACCA [18]. In our study, the first p16-M and p16-
U set is designated as CDKN2A MSP1 while the second p16-M2
and p16-U2 set is designated as CDKN2A MSP2. PTEN promoter
analysis was performed with the following two previously reported
primer sets: PTEN-I-M Forw TTTTTTTTCGGTTTTT-
CGAGGC, PTEN-I-M Rev CAATCGCGTCCCAACGCCG,
PTEN-I-U Forw TTTTGAGGTGTTTGGGTTTTTGGT,
PTEN-I-U Rev ACACAATCACATCCCAACACCA, PTEN-III-
M Forw GGTTTCGGAGGTCGTCGGC, PTEN-III-M Rev
CAACCGAATAATAACTACTACGACG, PTEN-III-U Forw
TGGGTTTTGGAGGTTGTTGGT, and PTEN-III-U Rev
ACTTAACTCTAAACCACAACCA [19]. In our study, the first
PTEN-I-M and PTEN-I-U set is designated as PTEN MSP1 while
the second PTEN-III-M and PTEN-III-U set is designated as
PTEN MSP2. PCR touchdown thermocycling conditions were as
follows: 95uC 5 minutes, [94uC 30 sec, 66uC 30 sec, 72uC
45 sec]62 cycles, [94uC 30 sec, 64uC 30 sec, 72uC 45 sec]62
cycles, [94uC 30 sec, 62uC 30 sec, 72uC 45 sec]62 cycles, [94uC
30 sec, 60uC 30 sec, 72uC 45 sec]634 cycles, 72uC 10 minutes.
PCR products were separated by 1.25% agarose gel electropho-
resis and visualized with ethidium bromide staining.
T (Brachyury) Quantitative Real-Time PCR
Purified genomic DNA from chordoma cases were analyzed by
Taqman quantitative real-time PCR in triplicate using two sets of
PCR primers/probes, one targeting the T (Brachyury) gene on
chromosome 6 and the other targeting the MCM7 gene on
chromosome 7 asa reference control. Theprimersets areasfollows:
T Forw 59-TCAGGAGTCAGAGTGCAGGA-39, T Rev 59-CGG-
ACCAGGATGAGAGAGAG -39, T Probe 59-[6-FAM]CGG-
CAGCATTTGTTGGGAGAAACG[Tamra]-39, MCM7 Forw
59-CGTGAGTGGAGAACTGACC-39, MCM7 Rev 59-CAGC-
CATCTTGTCGAACTC-39, and MCM7 Probe 59-[6-FAM]T-
GACCAGGGTGTGTGCTGCA[Tamra]-39. Reaction condi-
tions include 5 mL of DNA (diluted to approximately 5 ng/mL) or
genomic standards, 1.67 pmol each of forward/reverse primers and
probe, 200 mM dNTP, 1.2 mM MgCl2, and 0.5 U Platinum Taq
polymerase in 10 mL total reaction volume (all reagents from
Invitrogen). Promega Human Genomic DNA:Male was serially
diluted1:2tomake the genomicstandards(20,10, 5,2.5,1.25,0.63,
0.31, and 0.16 ng/mL or equivalently 6080, 3040, 1520, 760, 380,
190, 95, and 48 copies/mL). PCR was performed with the Applied
Biosystems 7500 Real-Time PCR System using the following
thermocycling conditions: 95uC 2 minutes, [94uC 15 sec, 60uC
60 sec]645 cycles. Ten non-chordoma blood DNA samples were
used to establish a normal reference T:MCM7 ratio. The test
samples were normalized to the normal reference ratio and further
corrected for MCM7 copy number status based on the array CGH
data and estimated tumor percentage based on histological review.
Finally, the normalized and corrected T:MCM7 ratios were
multipled by a factor of 2 to obtain the absolute estimated T copy
number.
Statistical Analysis
Statistical analyses were performed with the XLSTAT software
(version 2010.3.01; New York, NY). Genetic alterations were
compared between different groups and conditions by the two-
tailed unpaired Student’s t-test and Fisher’s exact test where
appropriate. Chordoma cases were evaluated by k-means
clustering based on quantitative PTEN immunofluorescence,
assuming two classes (positive and negative staining groups) and
using random initial partition. The Mann-Whitney U test was used
to confirm the segregation result from k-means clustering. P-values
of 0.05 or less were considered significant.
Results
Chordoma Cases
Frozen tumor specimens were obtained from 20 patients
including 14 males and 6 females who ranged in age from 41 to
83 (median 61.5) years. All tumors were classified as conventional,
sporadic chordomas by light microscopy except for one neoplasm
which was diagnosed as a chondroid subtype (CH9). Seventeen
samples were from the primary tumor and were located in the
sacrum (10 cases), clivus (2 cases), and the mobile spine (5 cases).
Four tumors were from local recurrences in the lumbar (CH6 and
CH39) and sacral spine (CH34 and CH37). Both CH34 and
CH37 were recurrent tumors from the same patient; the latter
recurrent CH37 tumor was excluded from all statistical analyses.
The majority of patients were treated with local radiation therapy
(15 out of 20 cases) and followed for disease survival since the time
of diagnosis. Nine patients died with an average survival of 8.2
years (range of 6–10 years, Table 1). No correlation was noted
between survival and various characteristics of the tumor or
patient, including age, gender, tumor location, tumor histology,
and radiation treatment.
Array CGH
Comparative genomic hybridization using the Agilent 244K
genome-wide oligonucleotide array showed predominantly copy
number losses involving an average of 26.5610.0% of the genome
per case (16.5% to 56.6% range, excluding the Y chromosome,
Figures 1 and 2). Copy number gains affected on average
7.167.2% of the genome per case (,0.1% to 27.1% range,
excluding the Y chromosome), which is significantly less than
involvement by copy number losses (P,0.01, Figures 1 and 2).
Frequent whole chromosome changes included losses of chromo-
somes 3 (75%), 4 (40%), 9 (45%), 10 (75%), 13 (55%), 14 (55%),
and 18 (40%). The most common chromosome gain involved
chromosome 7 which was found in a total of 5 cases (25%).
Copy Number Changes in Sporadic Chordomas
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Case Age Gender Location Histology XRT Followup Survival
CH1 70 M Sacrum Conventional Y A / NED N/A
CH2 53 M Clivus Conventional Y A N/A
CH3 75 F Lumbar Conventional Y D 11
CH5 73 M T11 Conventional N A N/A
CH6 41 M Lumbar (recurrent) Conventional N D 6
CH7 58 F Clivus Conventional Y D 10
CH8 60 F Sacrum Conventional Y A / NED N/A
CH9 45 F Cervical Chondroid Y A N/A
CH14 71 M Sacrum Conventional Y A / NED N/A
CH30 80 M Sacrum Conventional Y A / NED N/A
CH33 57 M Lumbar Conventional Y A N/A
CH34 73 M Sacrum (recurrent) Conventional Y D / NED 10
CH35 71 F Cervical Conventional Y D / NED 8
CH36 52 F Sacrum Conventional Y A N/A
CH37 74 M Sacrum (recurrent) Conventional Y D / NED 10
CH39 52 M Lumbar (recurrent) Conventional Y D 11
P527 77 M Sacrum Conventional N D 6
P554 55 M Sacrum Conventional N A N/A
P937 46 M Sacrum Conventional N A N/A
P984 83 M Sacrum Conventional Y D 6
P1033 63 M Sacrum Conventional Y D 6
XRT=Radiation therapy. A=Alive. D=Dead. NED=No evidence of disease. Survival in years from time of diagnosis. N/A=Not applicable. Note that cases CH34 and
CH37 are recurrent tumors from the same patient.
doi:10.1371/journal.pone.0018846.t001
Figure 1. Heat map of array CGH results. Copy number gains (red) and losses (green) are displayed for each individual chordoma case (rows)
with chromosomes organized in columns (separated by white vertical lines) and indicated by labels at the bottom. Note that cases CH34 and CH37
are recurrent tumors from the same patient.
doi:10.1371/journal.pone.0018846.g001
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maximal ranges and subranges of the involved regions are listed in
Table 2. Of note, entire and partial loss of 1p was found in all cases,
including three cases with partial telomeric 1p loss (CH14, CH39,
P937) and three cases with partial centromeric 1p loss (CH7, CH30,
P554).Lossof10q,eitherthroughentire chromosome 10lossor10q
loss only was evident in 16 of 20 cases (80%).
Loss of 9p, either through entire chromosome 9 loss or partial
9p loss alone, was observed in 15/20 cases (75%). Including one
case with a submicroscopic deletion of approximately 158 kilo-
bases involving CDKN2A only (CH7), 16 of 20 cases (80%)
demonstrated loss of the CDKN2A/CDKN2B gene, six (30%) of
which had a homozygous deletion of the gene (CH2, CH7, CH14,
CH34, CH36, and CH39). Various patterns of homozygous
CDKN2A/CDKN2B deletions were noted (Figure 3). Other
homozygous submicroscopic deletions were detected by array
CGH in regions of known benign copy number variation (CNV).
Homozygous deletions of other pertinent tumor suppressor genes
were not observed.
CDKN2A Immunohistochemistry and PTEN
Immunofluorescence
The frequent copy number losses of 9p and 10q in our cohort of
tumors directed our investigation into the loss of gene expression
of key tumor suppressor genes found in these two regions. We
performed protein immunostaining against CDKN2A and PTEN,
two important tumor suppressor proteins found in 9p and 10q,
respectively. Immunohistochemistry for CDKN2A showed loss of
expression in the majority of cases (15/18 or 83% of cases tested,
excluding CH37). Most of these cases demonstrated one or two
copy number loss of CDKN2A on array CGH. All of the tested
tumors with detected homozygous loss of CDKN2A on array CGH
showed loss of CDKN2A protein expression (CH2, CH14, CH34,
CH36, CH37, CH39) (Figure 4, top panels, and Table 3).
Interestingly, two cases with maintenance of two CDKN2A copies
also showed loss of CDKN2A expression (CH3 and CH33,
italicized and bolded in Table 3).
Automated quantitative analysis (AQUA) of in situ PTEN
expression using double immunofluorescence was utilized [16].
Anti-cytokeratin antibody, known to be a consistent marker for
conventional and chondroid chordoma [20], was used to label the
tumor cells green (AlexaFluor 555, Figure 4, bottom panels) and to
create a tumor specific mask within which red anti-PTEN signals
were automatically quantitated (CY5, Figure 4, bottom panels).
PTEN immunofluoresence demonstrated a typical punctate
nuclear and cytoplasmic staining pattern. Average pixel intensities
with associated standard deviations were used to cluster the tested
tumors into two distinct positive and negative staining groups by
applying k-means clustering (Table 4). A non-parametric Mann-
Whitney U test showed that these two groups are significantly
different (median for positive staining group: 641, median for
negative staining group: 108, U=84, n1=6, n2=14, P,0.0001,
two-tailed). The results indicate that most tumors with one copy
loss of PTEN had loss of PTEN expression (11/16, 69%) while
three out of four cases with maintenance of two PTEN copies
showed loss of PTEN expression. Interestingly, the second
recurrent CH37 tumor but not the first recurrent CH34 chordoma
showed loss of PTEN expression. No significant correlation was
noted between patient death and copy number status of CDKN2A/
B or PTEN, or expression of CDKN2A/B or PTEN.
CDKN2A and PTEN Methylation Specific PCR
CDKN2A and PTEN promoter hypermethylation was evaluated
by using methylation specific PCR (MSP). Two sets of previously
reported unmethylated and methylated specific primers were used
in a touchdown PCR protocol to amplify CpG islands in the
promoter regions after bisulfite treatment of the genomic DNA
[18], [19]. Only one tested chordoma case (CH33) showed
definitive evidence of CDKN2A promoter methylation with positive
PCR amplification products using both sets of methylation specific
Figure 2. Frequency plot by genomic position. Array CGH data from all chordoma cases from 20 unique patients were combined and presented
as copy number gain/loss frequencies relative to chromosome and genomic position. Note that chromosome Y is not depicted. The second recurrent
CH37 tumor was excluded from analysis.
doi:10.1371/journal.pone.0018846.g002
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methylation specific PCR results (positive amplification with only
one out of two primer sets) were obtained for five tested chordoma
cases (CH34, CH36, CH37, P527, and P984, Table 4). No tumors
showed definitive PTEN promoter methylation.
Genotyping
A previously described multiplex single base extension genotyp-
ing assay (based on Life Technologies/Applied Biosystems
SNaPshot technology) was applied to detect common point
mutations in various cancer genes [17]. In total, fifty-six bases in
various loci of the following genes were interrogated: APC,
CTNNB1, BRAF, EGFR, FLT3, JAK2, KIT, KRAS, NOTCH1, NRAS,
PIK3CA, PTEN, and TP53. No mutations in these common cancer
genes were found in any of the 21 tumor samples (data not shown).
PTEN exon 8 was further evaluated by reverse direction Sanger
sequencing which also revealed no mutations (data not shown).
T (Brachyury) Quantitative Real-Time PCR
The identification of germline T gene duplication in familial
chordomas [10] prompted us to perform quantitative real-time
PCR in our set of sporadic chordomas using one set of primer/
probe targeted to T and a reference control primer/probe set
targeted to MCM7. Relative T:MCM7 ratios were determined and
normalized against an average ratio established from a normal
control run of 10 non-chordoma genomic DNA samples (Figure 6).
All but two tested sporadic chordoma samples (CH14 and P554)
showed a normal T copy number of 2. A T copy number of
2.760.4 was determined for case CH14 and 3.860.4 for case
P554. A familial case of chordoma (family 4, patient 1) previously
reported to have T duplication [10], showed a T copy number of
approximately 9.561.0.
Discussion
Using the Agilent 244K genome wide CGH microarray, we
found numerous albeit recurrent and remarkably stereotypic
chromosomal abnormalities in sporadic chordomas. In aggregate,
the changes characterize a malignancy with significant genomic
instability. Copy number losses were more prevalent than copy
number gains, specifically 1p which was partially or completely
lost in all of our chordoma cases. Prior studies examining 1p have
described similar results, implicating in particular loss of the 1p36
Table 2. Recurrent genomic changes in sporadic chordoma.
Cytogenetic Locus Gain/Loss Maximum Range Subrange Frequency Candidate Genes
1p36.32-p11.1 Loss 0.74–121.05 0.55–52.39 0.85 RUNX3
52.39–72.81 0.80
72.81–121.05 0.80
3p29-p26.3 Loss 0.04–199.32 0.04–90.39 0.75 MLH1, VHL
95.07–196.78 0.75
0.04–196.78 0.70
4p16.3-q35.2 Loss 0.04–191.13 9.58–191.13 0.40
6q21-q22.33 Loss 113.47–127.54 113.47–127.54 0.25
7p36.3-p22.3 Gain 0.14–158.81 0.14–158.81 0.25
99.53–100.68 0.50
0.15–2.99 0.55
70.77–76.05 0.45
8q24.3 Gain 142.70–145.79 142.70–145.79 0.35
9p24.3-q34.3 Loss 0.21–140.15 0.21–140.15 0.25 TSC1, PTCH1
0.23–38.81 0.55 CDKN2A, CDKN2B
10p15.3-q26.3 Loss 0.12–135.25 0.12–135.25 0.65 PTEN
2.04–120.08* 0.80 PTEN
11p15.5-p11.12 Loss 0.18–50.64 0.18–50.64* 0.30 WT1
11q12.2-q13.4 Gain 60.24–72.78 60.24–72.78* 0.30 MEN1
13q11-q34 Loss 18.07–114.12 18.07–114.12* 0.60 RB, BRCA2
14q11.1-q32.33 Loss 18.62–106.35 18.62–106.35* 0.65
17p13.3-p11.1 Loss 0.06–22.14 0.06–22.14* 0.35 P53, NF1
17q11.1-q25.3 Gain 22.81–78.65 71.85–78.05 0.25 HER2
18p11.32-q23 Loss 0.06–76.11 0.06–76.11 0.40 SMAD4
19p13.3-q13.43 Gain 0.21–63.78 0.21–63.78* 0.30 TGFB1, BAX
0.21–19.72* 0.45
22q11.1-q13.33 Loss 14.50–49.57 14.50–49.57* 0.45 NF2, CHEK2
Selected copy number gains/losses of $25% frequency (occurring in at least 5 out of 20 cases from unique patients) are listed with details pertaining to cytogenetic loci,
genomic position, frequency, and candidate oncogenes or tumor suppressor genes. Involved maximal ranges and smaller subranges are included (coordinates in
megabases).
*=ranges with cases showing slight variations within the interval.
doi:10.1371/journal.pone.0018846.t002
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of chordoma and as a poor prognostic factor [15], [21], [22], [23].
An important tumor suppressor gene located in this locus is
RUNX3 which is often deleted or hypermethylated in various
cancers showing epithelial, hematopoietic, and neural phenotypes
[24]. Eighteen of twenty (90%) chordoma cases showed hemizy-
gous loss of 1p36, suggesting the relevance of examining RUNX3
as well as other potential 1p36 tumor suppressor genes in
chordomas in future studies (e.g., CDH5, TP73,o rCDKN2C).
Other common observed losses include chromosomes 3, 4, 9p,
9q, 10, 13, 14, 18, and 22. Common gains include chromosomes 7
and 19. These results mirror those found previously by Hallor et al.
although the frequencies of these changes in our study range from
10% to 30% more than in their report [15]. Similar to the work of
Hallor et al., the only consistent homozygous deletion that was
detected in our 21 chordoma cases involves 9p and specifically the
CDKN2A/CDKN2B genes. The loss of 9p is an established finding
in chordomas based on experiments involving FISH [8], [25] and
BAC array CGH [15]. The CDKN2A protein or p16, which is
encoded by the CDKN2A gene on the short arm of chromosome 9
(9p21), is a tumor suppressor gene that inhibits the function of
cdk4- and cdk6-cyclin D complexes. Cdk-cyclin complexes
regulate the retinoblastoma protein, thus controlling the G1-S
phase checkpoint of the cell cycle. CDKN2A inactivation thereby
can result in cellular proliferation [26].
Review of our array CGH data showed various mechanisms of
homozygous loss of CDKN2A only or CDKN2A/CDKN2B in 30% of
our cases (excluding CH37), including submicroscopic deletions in
the setting of 9p one copy loss (CH2, CH7, CH34, CH36, and
CH37), submicroscopic deletions alone (CH39), or deletions as
part of complex changes in 9p (CH14) (Figure 3). The
homozygous deletions ranged from approximately 76 kilobases
to 4.7 megabases. Interestingly, both the first and second recurrent
tumors from the same patient (CH34 and CH37, respectively)
shared the same affected probes in their homozygous copy loss,
spanning about 76 kb and involving only the CDKN2A gene. Of
note, the complex ‘‘saw-tooth,’’ alternating gain-loss pattern
observed with sample CH14 may reflect a similar pattern found
in a recently reported chordoma case showing a catastrophic
rearrangement phenomenon called ‘‘chromothripsis,’’ which also
involved chromosome 9p [27].
The frequencies at which we detected hemizygous and
homozygous deletions of the CDKN2A locus were overall higher
than those described by Hallor et al.: 10/20 or 50% hemizygous
and 6/20 or 30% homozygous (16/20 or 80% total) versus 15/26
or 58% hemizygous and 3/26 or 12% homozygous (18/26 or 69%
total). The difference in pickup rate may be attributed to our use of
a higher resolution Agilent 244K oligo array which affords higher
sensitivity in detecting smaller changes relative to the traditional
techniques applied in the Hallor et al. study, including karyotyping,
Figure 3. Chromosome 9 array CGH results. Array CGH results for chromosome 9 are shown for select chordoma cases showing homozygous
CDKN2A deletion. Plots were generated with the Agilent Genomic Workbench Standard Edition 5.0 software. The sizes of the homozygous deletions
for the five respective cases are as follows: 512 kb, 4.7 Mb, 76 kb, 76 kb, and 158 kb. Note that cases CH34 and CH37 are recurrent tumors from the
same patient. Cases CH7 (158 kb) and CH36 (1.9 Mb) also harbor homozygous CDKN2A deletions and are not depicted above. kb=kilobases,
Mb=megabases.
doi:10.1371/journal.pone.0018846.g003
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association between death and the presence of hemizygous or
homozygous 9p (containing CDKN2A) loss (Fisher’s exact test,
P=0.59, 2-tail) or the presence of homozygous 9p (containing
CDKN2A) loss alone (Fisher’s exact test, P=1, 2-tail).
Array CGH findings related to CDKN2A were correlated with
protein expression. Indeed immunohistochemistry for CDKN2A
confirmed loss of expression in 15/18 or 83% (excluding CH37)
of tested cases, including 8/11 tumors with hemizygous deletion,
5/5 tumors with homozygous deletion, and 2/2 tumors with copy
number maintenance. Other studies have also illustrated similar
results with regard to loss of CDKN2A expression [28], [29]. No
statistically significant association between death and CDKN2A
immunohistochemistry was found (Fisher’s exact test, P=0.56,
2-tail). In tumors with hemizygous deletions, loss of expression of
the remaining allele through promoter methylation of CDKN2A
may eliminate expression from the second non-deleted allele.
CDKN2A promoter methylation analysis using two sets of
methylation specific primers showed definitive promoter methyl-
ation in only one case (CH33) which explains the loss of
CDKN2A expression despite maintaining 2 copies of CDKN2A.
These results indicate promoter methylation may be a mecha-
nism of CDKN2A gene silencing in only a small subset of
chordomas.
The PTEN tumor suppressor gene is located on 10q23.3, a
region which showed hemizygous deletions in 80% of our
chordoma samples. No statistically significant association between
death and 10q (including PTEN) copy number status was found
(Fisher’s exact test, P=0.09, 2-tail). Quantitative immunofluores-
cence was applied to evaluate the expression of PTEN, showing
widespread loss of expression observed in 13/19 or 68% of the
tested tumors (excluding CH37). Three of these cases (CH1,
CH33, and CH36) had normal copy number status of the gene.
Interestingly, loss of PTEN expression was acquired in the second
recurrent CH37 tumor but not in the first recurrent CH34
chordoma of the same patient. Loss of PTEN expression was not
associated with patient death (Fisher’s exact test, P=1, 2-tail). The
frequent loss of PTEN expression is consistent with our recent
study describing hyperactivation of Akt/mTORC1 signaling in
sporadic sacral chordomas as a result of PTEN deficiency [30].
Methylation analysis of 4/5 tested cases with intact PTEN
expression did not show methylation of the PTEN promoter
region. In 5/15 tested cases (including CH34 which had intact
PTEN expression), equivocal PTEN methylation specific PCR
Figure 4. Top Panels: CDKN2A immunohistochemistry. Representative chordoma cases showing lack of expression (left, CH39) and strong
expression (right, CH35). Bottom Panels: PTEN Immunofluorescence. Representative chordoma cases were immunostained with anti-cytokeratin to
highlight tumor cells (green) and anti-PTEN (red). Tumor cells show lack of PTEN expression in the left panel and expression of PTEN in the right
panel. Note in both left panels that stromal tissue or normal cells show expression of CDKN2A and PTEN, but tumor areas indicated by arrows show
lack of expression.
doi:10.1371/journal.pone.0018846.g004
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the methylated target at nucleotide 2298 upstream in the
promoter sequence while the MSP1 primer set targeting
nucleotide 2984 did not. Both primer sets were reported to be
applicable in assessing PTEN promoter methylation status in a
manner specific to the putative gene rather than the pseudogene
[19]. It is possible that locus heterogeneity of CpG island
methylation may explain these results, a phenomenon which has
been reported for MGMT promoter methylation in glioblastomas
[31]. Without functional studies to characterize the methylation
effect of individual CpG islands on protein expression, our current
findings cannot definitively confirm or refute the role of promoter
methylation in the silencing of PTEN expression in sporadic
chordomas. However, if these five equivocal cases were truly
methylated, PTEN promoter methylation would account for 4/9
tested cases with loss of PTEN expression and therefore not be the
basis for gene silencing in the majority of chordoma cases with
PTEN deficiency.
We also explored whether genetic mutations may account for
the loss of PTEN expression/function. Our single base extension
genotyping SNaPshot platform (examining the common PTEN
R130*, R173C, R233*, K267fs*9 mutations) and Sanger
sequencing of PTEN exon 8 did not reveal any mutations in the
tested chordoma samples. Our SNaPshot assay also includes
primers to evaluate hotspot point mutations in other genes
commonly found in cancer including APC, CTNNB1, BRAF,
EGFR, FLT3, JAK2, KIT, KRAS, NOTCH1, NRAS, PIK3CA, and
TP53. No mutations in these genes were detected. Our negative
KRAS/BRAF results are similar to the negative findings of another
study which tested chordomas for KRAS and BRAF mutations and
their relationship with the FGFR-RAS/RAF/MEK/ERK-ETS2/
brachyury pathway [32].
The recent implication of T (brachyury) gene duplication in
familial chordoma [10] and T copy number gain in sporadic
chordoma [11] prompted us to search for a possible association
in our group of sporadic chordomas. The findings from the
work of Yang et al. suggested that the duplicated T region in
familial chordoma can range from 52 kb to 489 kb. The Agilent
244K microarray used in this study contains only two probes in
the T gene which are spaced 8216 bases apart (hg18) and are
therefore inadequate for evaluating T duplication. To more
accurately assess the copy number of T in our sporadic
chordoma samples, we applied quantitative real-time PCR.
The data suggest that unlike familial chordomas, the majority of
Table 3. CDKN2A analysis results.
CDKN2A CDKN2A CDKN2A CDKN2A
Case IHC MSP1 MSP2 Copy Number Status
CH1 + NP NP 1
CH2 2 UF0
CH3 2 NP NP 2
CH5 2 NP NP 1
CH6 + NP NP 1
CH7 NP U U 0
CH8 NP NP NP 2
CH9 2 NP NP 1
CH14 2 UU0
CH30 2 UU1
CH33 2 MM2
CH34 2 UU0
CH35 + UU1
CH36 2 UF0
CH37 2 UU0
CH39 2 UU0
P527 2 UU1
P554 2 UU1
P937 2 UU1
P984 2 MU1
P1033 2 UU1
Immunohistochemistry (IHC) was performed using standard protocol on
formalin-fixed paraffin-embedded tumor specimen to assess for expression of
CDKN2A (9p21.3). Methylation specific PCR was performed on bisulfite treated
DNA using two primers sets (MSP1 and MSP2) targeted to the promoter region
of CDKN2A. CDKN2A copy number status for each case is summarized from the
array CGH results. Italicized and bolded are two cases (CH3 and CH33) showing
loss of CDKN2A while maintaining normal CDKN2A copy number status.
NP=not performed. F=Technical failure. U=Unmethylated. M=Methylated.
CDKN2A copy number status based on array CGH: 0=Homozygous deletion,
1=Hemizygous deletion, 2=Copy number neutral.
doi:10.1371/journal.pone.0018846.t003
Table 4. PTEN analysis results.
PTEN PTEN PTEN PTEN
Case IF MSP1 MSP2 Copy Number Status
CH1 2 NP NP 2
CH2 2 FF1
CH3 2 NP NP 1
CH5 2 NP NP 1
CH6 2 NP NP 1
CH7 + UU1
CH8 NP NP NP 1
CH9 + NP NP 1
CH14 2 UU1
CH30 + UU2
CH33 2 UU2
CH34 + UM1
CH35 2 UU1
CH36 2 UM2
CH37 2 UM1
CH39 2 UU1
P527 2 UM1
P554 2 UU1
P937 + UU1
P984 2 UM1
P1033 + UU1
Immunofluorescence (IF) was performed on formalin-fixed paraffin-embedded
tumor specimen to assess for expression of PTEN (10q23.31) using the
previously described AQUA technique (see Materials & Methods). Methylation
specific PCR was performed on bisulfite treated DNA using two primers sets
(MSP1 and MSP2) targeted to the promoter region of PTEN. PTEN copy number
status for each case is summarized from the array CGH results. Italicized and
bolded are three cases (CH1, CH33, and CH36) showing loss of PTEN despite
maintainence of normal PTEN copy number status. NP=Not performed.
F=Technical failure. U=Unmethylated. M=Methylated. PTEN copy number
status based on array CGH: 0=Homozygous deletion, 1=Hemizygous deletion,
2=Copy number neutral.
doi:10.1371/journal.pone.0018846.t004
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amplification. Only two out of 16 analyzed cases (CH14 and
P554) showed an abnormal T copy number (approximately 3
and 4 copies per cell, respectively). A familial chordoma sample
(family 4, patient 1), which was tested in the Yang et al. study
and served as our positive control, showed amplification at
nearly 10 copies per cell. Our results are in line with the recent
Shalaby et al. study which utilized FISH and found no T
amplification in the majority of their 39 tested sporadic
chordoma cases and a minor T allelic gain (at approximately
a 3:1 ratio) in 3 samples [32]. In addition, Presneau et al. also
showed T amplification in 14 of 181 and minor allelic gain in 8
of 81 sporadic chordoma cases [11]. Our two cases which
showed T copy number gains (CH14 and P554) are consistent
with the minor T allelic gain observation in both the Shalaby et
al. and Presneau et al. studies.
In summary, we have shown that sporadic chordoma is a
malignant disease characterized by significant genomic instability
mostly due to large copy number losses. In addition to validating
previously reported cytogenetic findings from other studies, we
identified smaller, recurrent homozygous deletions in the
CDKN2A/CDKN2B locus. The frequent loss of chromosomal
regions containing CDKN2A and PTEN tumor suppressor genes
was associated with loss of protein expression which mechanisti-
cally does not appear to be due to promoter methylation in the
majority of cases and did not correlate with patient death.
Sporadic chordomas do not harbor point mutations in some of the
common cancer genes and are not associated with T duplication
or amplification in most cases. The findings indicate that the
majority of sporadic chordomas may rely on mechanisms other
than copy number gain if they indeed exploit T/brachury for
proliferation. Future studies should utilize high-throughput
genotyping methods such as next generation sequencing to
Figure 5. CDKN2A and PTEN methylation specific PCR. Bisulfite-
treated chordoma DNA samples were tested with methylation specific
PCR to evaluate for hypermethylation of the CDKN2A and PTEN
promoter regions. Two sets of unmethylated (U) and methylated (M)
PCR primers were used for each target gene (bottom labels, MSP1 and
MSP2). Unmethylated and methylated controls are shown along with
results for case CH33. Results for other tested cases are summarized in
Tables 3 and 4 under the CDKN2A and PTEN MSP1 and MSP2 columns.
Tick marks on the left and right of each panel indicate 100, 200, 300,
and 400 base pair sizes (bottom to top).
doi:10.1371/journal.pone.0018846.g005
Figure 6. T quantitative real-time PCR. Two primer/probe sets were used to quantitate T (6q27) and MCM7 (7q21.3-q22.1) (n=3). Relative
T:MCM7 ratios were normalized against an average ratio established from ten non-chordoma DNA samples (normal). The normalized ratios were
corrected for MCM7 copy number from array CGH data and approximate tumor percentage based on histological review. Corrected normalized ratios
were multiplied by 2 to obtain the absolute T copy number. The dashed line represents a normal copy number of 2.
doi:10.1371/journal.pone.0018846.g006
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the role of T in proliferation, and search for mutations outside of
known hotspots in cancer genes.
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